Memory and brain-derived neurotrophic factor after subchronic or chronic amphetamine treatment in an animal model of mania

Journal of Psychiatric Research

Volumn 68, Issue , 2015, Pages 329-336

  Fries, Gabriel R ^a,b   Valvassori, Samira S ^a,c   Bock, Hugo ^a,d   Stertz, Laura ^a,b   Magalhães, Pedro Vieira da Silva ^a,d   Mariot, Edimilson ^a,c   Varela, Roger B ^a,c   Kauer Sant'Anna, Marcia ^a,d   Quevedo, João ^a,b,c   Kapczinski, Flávio ^a,b,d   Saraiva Pereira, Maria Luiza ^a,d  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Amphetamine; Animal model; BDNF; Bipolar disorder; Mania; Memory

Indexed keywords

AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; SODIUM CHLORIDE; CENTRAL STIMULANT AGENT;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HABITUATION MEMORY; HIPPOCAMPUS; INHIBITORY AVOIDANCE MEMORY; LEARNING AND MEMORY TEST; LONG TERM CARE; MALE; MANIA; MEMORY; MENTAL PERFORMANCE; NEUROBIOLOGY; NONHUMAN; OPEN FIELD HABITUATION; PASSIVE AVOIDANCE TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRAINING; TREATMENT DURATION; WISTAR RAT; AMYGDALA; ANIMAL; ANIMAL BEHAVIOR; AVOIDANCE BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; HABITUATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMPHETAMINE; AMYGDALA; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HABITUATION, PSYCHOPHYSIOLOGIC; HIPPOCAMPUS; MALE; MEMORY; PREFRONTAL CORTEX; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 84937976789     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.05.006     Document Type: Article

References (61)

1. Angelucci F., Gruber S.H., El Khoury A., Tonali P.A., Mathé A.A. Chronic amphetamine treatment reduces NGF and BDNF in the rat brain. Eur Neuropsychopharmacol 2007, 17:756-762.
2. Arnsten A.F. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006, 31:2376-2383.
3. Bekinschtein P., Cammarota M., Izquierdo I., Medina J.H. BDNF and memory formation and storage. Neuroscientist 2008, 14:147-156.
4. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007, 434:41-49.
5. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35:804-817.
6. Bisagno V., Ferguson D., Luine V.N. Chronic D-amphetamine induces sexually dimorphic effects on locomotion, recognition memory, and brain monoamines. Pharmacol Biochem Behav 2003, 74:859-867.
7. Buoli M., Caldiroli A., Caletti E., Zugno E., Altamura A.C. The impact of mood episodes and duration of illness on cognition in bipolar disorder. Compr Psychiatry 2014, 55:1561-1566.
8. Cavanagh J.T.O., van Beck M., Muir W., Blackwood D.H. Case-control study of neurocognitive function in euthymic patients with alcohol disorder: an association with mania. Br J Psychiatry 2002, 180:320-326.
9. Chen C.H., Suckling J., Lennox B.R., Ooi C., Bullmore E.T. Aquantitative meta-analysis of fMRI studies in bipolar disorder. Bipolar Disord 2011, 13:1-15.
10. Chen Z.Y., Ieraci A., Teng H., Dall H., Meng C.X., Herrera D.G., et al. Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. JNeurosci 2005, 25:6156-6166.
11. Cryan J.F., Hoyer D., Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 2003, 54:49-58.
12. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Gonçalves C.A., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006, 398:215-219.
13. Cunha C., Brambilla R., Thomas K.L. Asimple role for BDNF in learning and memory?. Front Mol Neurosci 2010, 3:1-14.
14. Dencker D., Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res 2010, 207:78-83.
15. Denicoff K.D., Ali S.O., Mirsky A.F., Smith-Jackson E.E., Leverich G.S., Duncan C.C., et al. Relationship between prior course of illness and neuropsychological functioning in patients with bipolar disorder. JAffect Disord 1999, 56:67-73.
16. Duman R.S., Monteggia L.M. Aneurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
17. Elshahawi H.H., Essawi H., Rabie M.A., Mansour M., Beshry Z.A., Mansour A.N. Cognitive functions among euthymic bipolar I patients after a single manic episode versus recurrent episodes. JAffect Disord 2011, 130:180-191.
18. Fernandes B.S., Gama C.S., Ceresér K.M., Yatham L.N., Fries G.R., Colpo G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. JPsychiatr Res 2011, 45:995-1004.
19. Frey B.N., Andreazza A.C., Ceresér K.M., Martins M.R., Valvassori S.S., Réus G.Z., et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006, 79:281-286.
20. Fries G.R., Pfaffenseller B., Stertz L., Paz A.V., Dargél A.A., Kunz M., et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep 2012, 14:667-675.
21. Fumagalli F., Di Pasquale L., Caffino L., Racagni G., Riva M.A. Repeated exposure to cocaine differently modulates BDNF mRNA and protein levels in rat striatum and prefrontal cortex. Eur J Neurosci 2007, 26:2756-2763.
22. Izquierdo I., Quillfeldt J.A., Zanatta M.S., Quevedo J., Schaeffer E., Schmitz P.K., et al. Sequential role of hippocampus and amygdala, entorhinal cortex and parietal cortex in formation and retrieval of memory for inhibitory avoidance in rats. Eur J Neurosci 1997, 9:786-793.
23. Kalinichev M., Dawson L.A. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol 2011, 14:1051-1067.
24. Kapczinski F., Frey B.N., Kauer-Sant'Anna M., Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 2008, 8:1101-1113.
25. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Young L.T. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009, 12:447-458.
26. Kesner R.P., Bierley R.A., Pebbles P. Short-term memory: the role of d-amphetamine. Pharmacol Biochem Behav 1981, 15:673-676.
27. Kesner R.P., Hunt M.E., Williams J.M., Long J.M. Prefrontal cortex and working memory for spatial response, spatial location, and visual object information in the rat. Cereb Cortex 1996, 6:311-318.
28. Kessing L.V., Andersen P.K. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?. JNeurol Neurosurg Psychiatry 2004, 75:1662-1666.
29. Küppers E., Beyer C. Dopamine regulates brain-derived neurotrophic factor (BDNF) expression in cultured embryonic mouse striatal cells. Neuroreport 2001, 12:1175-1179.
30. Lin P.Y. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009, 466:139-143.
31. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
32. Lyoo I.K., Sung Y.H., Dager S.R., Friedman S.D., Lee J.Y., Kim S.J., et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 2006, 8:65-74.
33. Macêdo D.S., Medeiros C.D., Cordeiro R.C., Sousa F.C., Santos J.V., Morais T.A., et al. Effects of alpha-lipoic acid in an animal model of mania induced by D-amphetamine. Bipolar Disord 2012, 14:707-718.
34. Machado-Vieira R., Kapczinski F., Soares J.C. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:209-224.
35. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001, 35:5-49.
36. Martínez-Arán A., Vieta E., Reinares M., Colom F., Torrent C., Sánchez-Moreno J., et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004, 161:262-270.
37. Mavrikaki M., Nomikos G.G., Panagis G. Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania. Int J Neuropsychopharmacol 2010, 13:541-548.
38. McCann U.D., Kuwabara H., Kumar A., Palermo M., Abbey R., Brasic J., et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008, 62:91-100.
39. Meredith G.E., Callen S., Scheuer D.A. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 2002, 949:218-227.
40. Merikangas K.R., Akiskal H.S., Angst J., Greenberg P.E., Hirschfeld R.M., Petukhova M., et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007, 64:543-552.
41. Ou L.C., Gean P.W. Transcriptional regulation of brain-derived neurotrophic factor in the amygdala during consolidation of fear memory. Mol Pharmacol 2007, 72:350-358.
42. Pathiraja A., Marazziti D., Cassano G.B., Diamond B.I., Borison R.L. Phenomenology and neurobiology of cocaine withdrawal: are they related?. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:1021-1034.
43. Richter-Levin G., Akirav I. Amygdala-hippocampus dynamic interaction in relation to memory. Mol Neurobiol 2000, 22:11-20.
44. Rodríguez-Casado A., Alvarez I., Toledano A., de Miguel E., Carmona P. Amphetamine effects on brain protein structure and oxidative stress as revealed by FTIR microspectroscopy. Biopolymers 2007, 86:437-446.
45. Rosa A.R., González-Ortega I., González-Pinto A., Echeburúa E., Comes M., Martínez-ran A., et al. One year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand 2012, 125:335-341.
46. Rossato J.I., Bevilaqua L.R., Izquierdo I., Medina J.H., Cammarota M. Dopamine controls persistence of long-term memory storage. Science 2009, 325:1017-1020.
47. Russig H., Durrer A., Yee B.K., Murphy C.A., Feldon J. The acquisition, retention and reversal of spatial learning in the morris water maze task following withdrawal from an escalating dosage schedule of amphetamine in Wistar rats. Neuroscience 2003, 119:167-179.
48. Shaltiel G., Chen G., Manji H.K. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 2007, 7:22-26.
49. Stokes A.H., Hastings T.G., Vrana K.E. Cytotoxic and genotoxic potential of dopamine. JNeurosci Res 1999, 55:659-665.
50. 2+ influx regulates BDNF transcription by a CREB family transcription factor. Neuron 1998, 20:709-726.
51. Thompson J.M., Gallagher P., Hughes J.H., Watson S., Gray J.M., Ferrier I.N., et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005, 186:32-40.
52. Torrent C., Martinez-Arán A., del Mar Bonnin C., Reinares M., Daban C., Solé B., et al. Long-term outcome of cognitive impairment in bipolar disorder. JClin Psychiatry 2012, 73:e899-905.
53. Torres I.J., Boudreau V.G., Yatham L.N. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl 2007, 434:17-26.
54. Tropea D., Capsoni S., Tongiorgi E., Giannotta S., Cattaneo A., Domenici L. Mismatch between BDNF mRNA and protein expression in the developing visual cortex: the role of visual experience. Eur J Neurosci 2001, 13:709-721.
55. Valvassori S.S., Budni J., Varela R.B., Quevedo J. Contributions of animal models to the study of mood disorders. Rev Bras Psiquiatr 2013, 35(Suppl.2):S121-S131.
56. Vianna M.R., Izquierdo L.A., Barros D.M., de Souza M.M., Rodrigues C., Sant'Anna M.K., et al. Pharmacological differences between memory consolidation of habituation to an open field and inhibitory avoidance learning. Braz J Med Biol Res 2001, 34:233-240.
57. Xu T.X., Ma Q., Spealman R.D., Yao W.D. Amphetamine modulation of long-term potentiation in the prefrontal cortex: dose dependency, monoaminergic contributions, and paradoxical rescue in hyperdopaminergic mutant. JNeurochem 2010, 115:1643-1654.
58. Yamamoto B.K., Moszczynska A., Gudelsky G.A. Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 2010, 1187:101-121.
59. Yamamoto B.K., Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. JNeuroimmune Pharmacol 2008, 3:203-217.
60. Zanatta M.S., Quillfeldt J.H., Schaeffer E., Schmitz P.K., Quevedo J., Medina J.H., et al. Involvement of the hippocampus, amygdala, entorhinal cortex and posterior parietal cortex in memory consolidation. Braz J Med Biol Res 1997, 30:235-240.
61. Zorick T., Nestor L., Miotto K., Sugar C., Hellemann G., Scanlon G., et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 2010, 105:1809-1818.